V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Halozyme Therapeutics Executive Compensation (FY25)

HALO · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Helen Torley
Latest say-on-pay support
=
May 5, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Halozyme Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): May 7, 2026
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Halozyme Therapeutics brief$1,500Get the executive brief
Velarion Member, one year
401 figures on this page: 390 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Helen Torley: $12,741,421 → $23,166,223 (81.8% higher)
Say-on-pay support: 96.1% → 90.1% (6.0 points lower)
CEO pay ratio: 58:1 → 100.1:1 (72.6% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Halozyme Therapeutics' chief executive and what were they paid?
Helen Torley, President and Chief Executive Officer, received $23,166,223 in total compensation for fiscal 2025. Torley's total was 81.8% higher than the $12,741,421 reported for fiscal 2024.
What was Halozyme Therapeutics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 90.1% of votes cast for or against in favor at the meeting held May 5, 2026.
Which companies are in Halozyme Therapeutics' peer group?
Companies named in the disclosed peer group include Acadia Pharmaceuticals, Alkermes, Amicus Therapeutics, Apellis Pharmaceuticals and BeiGene, among others.
What is Halozyme Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 100.1:1 for fiscal 2025, against median employee compensation of $231,329.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Helen Torley
President and Chief Executive Officer
◇—◇◇◇—◇◇
Mark Snyder
Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
◇—◇◇◇—◇◇
Michael LaBarre
Senior Vice President, Chief Technical Officer
◇—◇◇◇—◇◇
Nicole LaBrosse
Senior Vice President Chief Financial Officer
◇—◇◇◇—◇◇
Elaine Sun
Former Senior Vice President Chief Financial Officer
Departed during or after this year
◇—————◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Helen Torley
President and Chief Executive Officer
◇—◇◇◇—◇◇
Nicole LaBrosse
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Mark Snyder
Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
◇—◇◇◇—◇◇
Michael LaBarre
Former Senior Vice President, Chief Technical Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Helen Torley
President and Chief Executive Officer
◇—◇◇◇—◇◇
Mark Snyder
Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
◇—◇◇◇—◇◇
Nicole LaBrosse
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Michael LaBarre
Former Senior Vice President, Chief Technical Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Helen Torley
President and Chief Executive Officer
◇—◇◇◇—◇◇
Nicole LaBrosse
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Mark Snyder
Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
◇—◇◇◇—◇◇
Cortney Caudill
Senior Vice President, Chief Operating Officer
◇—◇◇◇—◇◇
Michael LaBarre
Former Senior Vice President, Chief Technical Officer
Departed during or after this year
◇—◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Cortney CaudillRSU◇——◇——◇
Cortney CaudillRSU◇——◇——◇
Cortney CaudillOPTION◇——◇—◇◇
Cortney CaudillPSU◇◇◇—◇—◇
Cortney CaudillPSU◇◇◇—◇—◇
Cortney CaudillOPTION◇——◇—◇◇
Helen I. TorleyPSU◇◇◇—◇—◇
Helen I. TorleyPSU◇◇◇—◇—◇
Helen I. TorleyRSU◇——◇——◇
Helen I. TorleyPSU◇◇◇—◇—◇
Helen I. TorleyOPTION◇——◇—◇◇
Mark SnyderPSU◇◇◇—◇—◇
Mark SnyderPSU◇◇◇—◇—◇
Mark SnyderRSU◇——◇——◇
Mark SnyderOPTION◇——◇—◇◇
Michael J. LaBarrePSU◇◇◇—◇—◇
Michael J. LaBarreOPTION◇——◇—◇◇
Michael J. LaBarreRSU◇——◇——◇
Michael J. LaBarrePSU◇◇◇—◇—◇
Nicole LaBrosseRSU◇——◇——◇
Nicole LaBrossePSU◇◇◇—◇—◇
Nicole LaBrossePSU◇◇◇—◇—◇
Nicole LaBrosseOPTION◇——◇—◇◇
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Helen TorleyPSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/23/2034
Option◇—◇2/16/2033
Option◇—◇2/16/2032
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/20/2035
Mark SnyderRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇1/3/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/16/2033
Option◇—◇2/23/2034
PSU◇◇——
Option◇—◇2/20/2035
PSU◇◇——
RSU◇◇——
Nicole LaBrossePSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/23/2034
RSU◇◇——
RSU◇◇——
Option◇—◇2/16/2032
Option◇—◇2/16/2033
Option◇—◇2/20/2035
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Cortney CaudillOption◇—◇11/1/2033
RSU◇◇——
RSU◇◇——
Option◇—◇10/3/2035
Option◇—◇2/20/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jeffrey W. Henderson
Board chair
◇◇◇———◇
Barbara Duncan
◇◇◇———◇
Matthew L. Posard
◇◇◇———◇
Bernadette Connaughton
◇◇◇———◇
Mahesh Krishnan
◇◇◇———◇
Moni Miyashita
◇◇◇———◇
Connie L. Matsui
◇—————◇
James Lang
◇—————◇
Helen I. Torley served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as RSUs and Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Acadia Pharmaceuticals ACAD
  • Alkermes ALKS
  • Amicus Therapeutics FOLD
  • Apellis Pharmaceuticals APLS
  • BeiGene symbol not shown
  • BioMarin Pharmaceutical BMRN
  • Blueprint Medicines BPMC
  • Denali Therapeutics DNLI
  • Exelixis EXEL
  • Insmed INSM
  • Intra-Cellular Therapeutics ITCI
  • Ionis Pharmaceuticals IONS
  • Ironwood Pharmaceuticals IRWD
  • Neurocrine Biosciences NBIX
  • PTC Therapeutics PTCT
  • Sarepta Therapeutics SRPT
  • Ultragenyx Pharmaceuticals RARE
  • United Therapeutics UTHR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 5, 2026=◇◇◇
2024May 1, 2025=◇◇◇
2023April 25, 2024=◇◇◇
2022May 5, 2023=◇◇◇
2021May 5, 2022=◇◇◇
2020May 5, 2021=◇◇◇
2019April 30, 2020=◇◇◇
2018May 2, 2019=◇◇◇
2017May 2, 2018=◇◇◇
2016May 4, 2017=◇◇◇
2015May 4, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Helen Torley (President and Chief Executive Officer), FY2025 total compensation $23,166,223 (base salary $1,000,000) [exec_comp, SEC accession 0001159036-26-000041, filed 2026-03-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Halozyme Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Halozyme Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Halozyme Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Halozyme Therapeutics' disclosed peer group is defensible, who names Halozyme Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
401 figures on this page: 390 cited to the filing that reported them, 11 calculated from figures it prints.
390 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001159036-26-000057
    Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes
  2. 0001159036-26-000041
    2025 Summary Compensation Table · CEO Pay Ratio · DIRECTOR COMPENSATION · Directors' Compensation · and 1 more section
  3. 0001159036-25-000022
    Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes
  4. 0001159036-25-000016
    2024 Summary Compensation Table
  5. 0001159036-24-000031
  6. 0001159036-24-000024
    2023 Summary Compensation Table
  7. 0001159036-23-000033
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001159036-23-000029
  9. 0001159036-22-000032
  10. 0001159036-21-000032
  11. 0001159036-20-000024
  12. 0001159036-19-000019
  13. 0001159036-18-000027
  14. 0001159036-17-000021
  15. 0001159036-16-000109
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Halozyme Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/HALO (accessed 2026).
Short form: data: Velarion

The Halozyme Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Halozyme Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Halozyme Therapeutics discloses

The companies named in HALO's own disclosed peer group.

Acadia PharmaceuticalsAlkermesAmicus TherapeuticsApellis PharmaceuticalsBioMarin PharmaceuticalBlueprint MedicinesDenali TherapeuticsExelixisInsmedIntra-Cellular TherapeuticsIonis PharmaceuticalsIronwood PharmaceuticalsNeurocrine BiosciencesPTC TherapeuticsSarepta TherapeuticsUltragenyx PharmaceuticalsUnited Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy